ReviewCurrent hypertension reports2014
ACE2: angiotensin II/angiotensin-(1-7) balance in cardiac and renal injury.
Review in Current hypertension reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed.
- Trial
- Protective Arm of Renin-Angiotensin System: Evidence of Nephroprotective Effects Against Acute Kidney Injury.Acta physiologica (Oxford, England) · 2026Review
- Association of ACE2 gene polymorphisms with risk of pulmonary arterial hypertension in neonates with congenital heart disease.BMC cardiovascular disorders · 2026Article
- Exploratory Analysis of Plasma Angiotensin-Converting Enzyme 2 and Angiotensin Peptides as Candidate Discriminatory Signals in Breast Cancer: A Pilot Case-Control Study.Biomedicines · 2026Article
- Systemic Arterial Hypertension and Factors Associated with Blood Pressure Dysregulation in Companion Animals.Veterinary sciences · 2025Review
- Interaction of SARS-CoV-2 and SARS-CoV-2 vaccines with renin angiotensin aldosterone system, clinical outcomes, and angiotensin (1-7) as a physiological treatment recommendation: hypothesis and theory article.Frontiers in medicine · 2025Article
- Radiation Induced Skin Fibrosis (RISF): Opportunity for Angiotensin II-Dependent Intervention.International journal of molecular sciences · 2024Review
- Novel Insights into the Cardioprotective Effects of the Peptides of the Counter-Regulatory Renin-Angiotensin System.Biomedicines · 2024Review
- Renin-Angiotensin System Components and Arachidonic Acid Metabolites as Biomarkers of COVID-19.Biomedicines · 2023Article
- Signaling Pathways and Potential Therapeutic Strategies in Cardiac Fibrosis.International journal of molecular sciences · 2023Review
- Soluble (Pro)renin Receptor Is Adversely Associated with Indices of Left Ventricular Structure and Function: The African-PREDICT Study.Journal of cardiovascular development and disease · 2022Article
- Insights into Cardiovascular Defects and Cardiac Epigenome in the Context of COVID-19.Epigenomes · 2022Review
- View of the Renin-Angiotensin System in Acute Kidney Injury Induced by Renal Ischemia-Reperfusion Injury.Journal of the renin-angiotensin-aldosterone system : JRAAS · 2022Review
- Renal Denervation Influences Angiotensin II Types 1 and 2 Receptors.International journal of nephrology · 2022Review
- Children With Short Stature Display ReducedFrontiers in endocrinology · 2022Article
- Review
- Higher Soluble ACE2 Levels and Increased Risk of Infection-Related Hospitalization in Patients on Maintenance Hemodialysis.Frontiers in medicine · 2022Article
- Possible Benefits of Zinc supplement in CVD and COVID-19 Comorbidity.Journal of infection and public health · 2021Review
- The effect of RAAS inhibitors on acute hypoxemic respiratory failure and in-hospital mortality in the hypertensive Covid-19 patients.Clinical and experimental hypertension (New York, N.Y. : 1993) · 2021Article
- Mesenchymal stem cells and COVID-19: What they do and what they can do.World journal of stem cells · 2021Review
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Our current recognition of the renin-angiotensin system is more convoluted than originally thought due to the discovery of multiple novel enzymes, peptides, and receptors inherent in this interactive biochemical cascade. Over the last decade, angiotensin-converting enzyme 2 (ACE2) has emerged as a key player in the pathophysiology of hypertension and cardiovascular and renal disease due to its pivotal role in metabolizing vasoconstrictive/hypertrophic/proliferative angiotensin II into favorable angiotensin-(1-7). This review addresses the considerable advancement in research on the role of tissue ACE2 in the development and progression of hypertension and cardiac and renal injury. We summarize the results from recent clinical and experimental studies suggesting that serum or urine soluble ACE2 may serve as a novel biomarker or independent risk factor relevant for diagnosis and prognosis of cardiorenal disease. We also review recent proceedings on novel therapeutic approaches to enhance ACE2/angiotensin-(1-7) axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.